The Relationship between Plasma Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease

الملخص EN

Background.

Inflammation is involved in the development and progression of coronary artery disease (CAD).

The role of the receptor for advanced glycation end products (RAGE) in the development of CAD has been recognized.

The expression of sRAGE and S100A12 in patients with coronary artery disease from different studies was inconsistent.

We attempted to determine the expression of sRAGE and S100A12 and their relationship in the subjects with different severity levels of CAD.

Methods.

A total of 259 patients undergoing coronary angiography were enrolled from the Department of Geriatric Cardiology in the First Affiliated Hospital of Nanjing Medical University from January 2014 to December 2016.

Groups were divided as follows: normal coronary artery (control group), nonobstructive coronary atherosclerosis (<50% stenosis in all coronary vessels, NOCA group), stable angina (SAP group), and acute coronary syndrome (ACS group).

During CAG or PCI, peripheral arterial blood was collected from all the patients.

Plasma sRAGE and S100A12 levels were measured by ELISA.

We calculated the SYNTAX score of each patient with CAD according to the result of CAG.

Results.

The levels of sRAGE were significantly elevated in the ACS group compared with those in the control group, the NOCA group, and the SAP group.

sRAGE levels were similar among the control group, the NOCA group, and the SAP group.

Plasma S100A12 levels were significantly higher in the ACS group than in the control group and the NOCA group.

Baseline correlations between plasma levels of sRAGE and plasma S100A12 in the ACS group were significant.

Plasma sRAGE concentration was increasing in patients with ACS and was significantly positively correlated with the increasing SYNTAX score.

ROC curve analysis revealed that the combination of sRAGE and S100A12 had a good performance in the prediction of high-risk CAD patients.

Conclusion.

The plasma levels of sRAGE and S100A12 can be increased in patients with ACS.

The elevated sRAGE concentration may be independently associated with the severity of CAD and the inflammatory process.

sRAGE combined with S100A12 may be used as a predictor of severe coronary heart disease.